The Food and Drug Administration (FDA) continued its efforts to modernize drug development and regulation with the recent publication of a notice in the Federal Register from the Center for Drug Evaluation and Research’s (CDER) Quantitative Medicine Center of Excellence announcing a request for information (RFI) to inform the development of the Quantitative Medicine Innovation Network (QMIN). The agency is seeking to better understand current quantitative medicine capabilities, challenges, and opportunities and specific feedback on how it might shape the structure, priorities and activities of this proposed collaborative ecosystem to advance the science and application of quantitative medicine in furtherance of public health.